From GlobeNewswire: 2025-04-02 16:15:00

Nanobiotix’s global development program for JNJ-1900 (NBTXR3) is proceeding as planned, focusing on head and neck cancer and lung cancer. The company’s financial strategy aims for long-term sustainability and growth, with a cash runway extended into mid-2026 and a reduction in operational cash burn. Clinical data readouts from various studies are expected in 2025.

Curadigm, a next-generation nanotherapeutic platform, has been launched by Nanobiotix, reshaping drug design and development. The company reported €49.7 million in cash and cash equivalents as of December 31, 2024, extending its cash runway. Clinical data readouts from Phase 1 and 2 studies in various cancers are anticipated in 2025.

Nanobiotix has strengthened its financial position through a disciplined approach, receiving milestone payments and amending global licensing agreements. The company’s net loss for the year ended December 31, 2024, was €68.1 million, with €49.7 million in cash and cash equivalents. Nanobiotix anticipates its cash will fund operations into mid-2026.

A conference call and webcast are scheduled for April 3, 2025, to discuss Nanobiotix’s operational progress, financial results, and strategic initiatives. The company’s focus on JNJ-1900 (NBTXR3) and the launch of Curadigm are key drivers of its long-term growth strategy. Participants can join the call to learn more about Nanobiotix’s plans for 2025 and beyond.



Read more at GlobeNewswire:: NANOBIOTIX Provides Business Update and Reports Full Year